Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer

  • Authors:
    • Hisami Fukuda
    • Norihiko Tsuchiya
    • Shintaro Narita
    • Teruaki Kumazawa
    • Yohei Horikawa
    • Takamitsu Inoue
    • Mitsuru Saito
    • Takeshi Yuasa
    • Shinobu Matsuura
    • Shigeru Satoh
    • Osamu Ogawa
    • Tomonori Habuchi
  • View Affiliations

  • Published online on: November 1, 2007     https://doi.org/10.3892/or.18.5.1155
  • Pages: 1155-1163
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Vascular endothelial growth factor (VEGF), one of the most potent angiogenic factors, is suggested to play a crucial role in tumor neovascularization and is associated with tumor progression and metastasis in prostate cancer. This study evaluated the significance of the VEGF T-460C polymorphism in the risk and the progression of prostate cancer. In a case-control experiment, 270 patients with prostate cancer and 252 male controls were investigated to assess the association of the VEGF T-460C polymorphism with the risk of prostate cancer. Prostate-specific antigen (PSA) recurrence in 95 patients who underwent radical prostatectomy and survival in 99 patients with metastases at diagnosis were analyzed to evaluate the influence of the polymorphism in cancer progression. The CC and TC genotypes of the polymorphism were associated with significantly higher rates of PSA recurrence after radical prostatectomy than the TT genotype and were independent predictors of PSA recurrence (P=0.011) in a multivariate analysis. In contrast, metastatic prostate cancer patients with the TT genotype showed significantly worse survival as compared to the CC and TC genotypes. In a multivariate analysis, the TT genotype was an independent predictor of cancer-specific survival (P=0.006). The VEGF T-460C polymorphism may have a substantial impact on both PSA recurrence after radical prostatectomy and survival in advanced prostate cancer. The molecular mechanisms of the polymorphism on the differing status in prostate cancer should be elucidated in further studies.

Related Articles

Journal Cover

November 2007
Volume 18 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fukuda H, Tsuchiya N, Narita S, Kumazawa T, Horikawa Y, Inoue T, Saito M, Yuasa T, Matsuura S, Satoh S, Satoh S, et al: Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol Rep 18: 1155-1163, 2007.
APA
Fukuda, H., Tsuchiya, N., Narita, S., Kumazawa, T., Horikawa, Y., Inoue, T. ... Habuchi, T. (2007). Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncology Reports, 18, 1155-1163. https://doi.org/10.3892/or.18.5.1155
MLA
Fukuda, H., Tsuchiya, N., Narita, S., Kumazawa, T., Horikawa, Y., Inoue, T., Saito, M., Yuasa, T., Matsuura, S., Satoh, S., Ogawa, O., Habuchi, T."Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer". Oncology Reports 18.5 (2007): 1155-1163.
Chicago
Fukuda, H., Tsuchiya, N., Narita, S., Kumazawa, T., Horikawa, Y., Inoue, T., Saito, M., Yuasa, T., Matsuura, S., Satoh, S., Ogawa, O., Habuchi, T."Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer". Oncology Reports 18, no. 5 (2007): 1155-1163. https://doi.org/10.3892/or.18.5.1155